Baseline | w12 | pa | w24 | pb | |
---|---|---|---|---|---|
Nr. of patients (%) | 126 (100.0) | 97 (77.0) | / | 66 (52.4) | / |
Disease-Clinimetric Indexes | |||||
Tender Joint Count, mean ± SD | 9.36 ± 6.76 | 4.05 ± 4.70 | < 0.001 | 3.59 ± 6.35 | < 0.001 |
Swollen Joint Count, mean ± SD | 3.02 ± 3.06 | 1.09 ± 2.53 | < 0.001 | 0.86 ± 2.19 | < 0.001 |
Leeds Enthesitis Index, mean ± SD | 0.91 ± 1.41 | 0.33 ± 0.78 | < 0.001 | 0.32 ± 0.77 | 0.0033 |
PASI, mean ± SD | 1.34 ± 4.17 | 0.42 ± 1.06 | 0.0094 | 0.69 ± 3.15 | 0.0373 |
PtGA (scale 0–100) mean ± SD | 71.99 ± 16.6 | 43.42 ± 20.9 | < 0.001 | 36.06 ± 21.6 | < 0.001 |
PGA (scale 0–100) mean ± SD | 63.11 ± 16.2 | 31.92 ± 21.1 | < 0.001 | 28.56 ± 23.8 | < 0.001 |
VAS (scale 0–100) mean ± SD | 71.21 ± 18.0 | 42.50 ± 24.7 | < 0.001 | 33.11 ± 23.0 | < 0.001 |
HAQ, mean ± SD | 1.24 ± 0.90 | 0.66 ± 0.78 | 0.0709 | 0.44 ± 0.56 | 0.0075 |
C-Reactive Protein, mg/dl | 0.99 ± 1.80 | 0.40 ± 0.75 | < 0.001 | 0.35 ± 0.83 | < 0.001 |
Composite Scores, global | |||||
MDA nr. (%) | 0 (0.0) | 29 (30.9) | / | 31 (47.0) | / |
VLDA nr. (%) | 0 (0.0) | 9 (9.6) | / | 9 (13.6) | / |
DAPSA, mean ± SD | 27.65 ± 10.0 | 14.05 ± 9.48 | < 0.001 | 11.77 ± 10.7 | < 0.001 |
DAPSA minor improvement, nr. (%) | / | 47 (48.5) | / | 44 (66.7) | / |
DAPSA moderate improvement, nr. (%) | / | 23 (23.7) | / | 26 (39.4) | / |
DAPSA major improvement, nr. (%) | / | 12 (12.4) | / | 15 (22.7) | / |
DAPSA LDA, nr. (%) | 0 (0.0) | 41 (42.3) | / | 35 (53.0) | / |
DAPSA remission status, nr. (%) | 0 (0.0) | 14 (14.4) | / | 15 (22.7) | / |
Composite Scores, axial | |||||
Nr. of patients with axial involvement (%) | 54 (100) | 38 (70.4) | / | 23 (42.6) | / |
ASDAS-CRP, mean ± SD | 2.65 ± 0.69 | 1.71 ± 0.79 | < 0.001 | 1.43 ± 0.78 | 0.0019 |
ASDAS-CRP CII, nr. (%) | / | 18 (47.4) | / | 15 (65.2) | / |
ASDAS-CRP MI, nr. (%) | / | 4 (10.5) | / | 8 (34.8) | / |
ASDAS-CRP LDA status, nr. (%) | 0 (0.0) | 12 (31.6) | / | 9 (39.1) | / |
ASDAS-CRP inactive disease status, nr. (%) | 0 (0.0) | 12 (31.6) | / | 11 (47.8) | / |